Know Cancer

or
forgot password

A Pilot Study Evaluating the Correlation Between Carbon 11 Acetate (C-11 Acetate) Uptake and Retention as Measured by Positron Emission Tomography (PET) and Fatty Acid Synthase (FAS) Expression in Prostate Cancer


N/A
18 Years
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

A Pilot Study Evaluating the Correlation Between Carbon 11 Acetate (C-11 Acetate) Uptake and Retention as Measured by Positron Emission Tomography (PET) and Fatty Acid Synthase (FAS) Expression in Prostate Cancer


- Within 4 weeks of the patient's scheduled surgery they will undergo a C11 acetate PET
scan. This scan will be performed at the Massachusetts General Hospital's Nuclear
Medicine Department and involves an intravenous injection of acetate with a radioactive
tracer followed by a PET scan. The scan will determine how well the tumor is taking up
the acetate.

- Patients will also undergo a CT scan of the pelvis at the same time as the PET scan.

- After surgery, the removed tumor will have additional testing that will look at
different factors that may tell us how aggressive the tumor is and how much FAS is
within the tumor. FAS seems to be produced in higher amounts by prostate cancer cells
than normal cells. We will then try to determine if the results of the C11 acetate PET
scan can tell us how much FAS is produced by prostate cancer cells.


Inclusion Criteria:



- Histologically documented prostate cancer

- Planned radical prostatectomy

- > 50% cores positive for prostate cancer from prostate biopsy or a palpable prostate
nodule

- Older than 18 years of age

Exclusion Criteria:

- Inability to lay on a scanner for 60 minutes

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To explore the associations between measures of C-11 acetate uptake and retention into prostate tumors and levels of FAS expression in tissue.

Principal Investigator

Robert Ross, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute

Authority:

United States: Institutional Review Board

Study ID:

05-136

NCT ID:

NCT00139191

Start Date:

July 2005

Completion Date:

May 2006

Related Keywords:

  • Prostate Cancer
  • Prostate Cancer
  • positron emission tomography
  • carbon 11 acetate
  • PET
  • fatty acid synthase
  • FAS
  • Prostatic Neoplasms

Name

Location

Beth Israel Deaconess Medical CenterBoston, Massachusetts  02215
Dana-Farber Cancer InstituteBoston, Massachusetts  02115
Massachusetts General HospitalBoston, Massachusetts  02114-2617